Shire agrees to AbbVie's $53bn takeover
This article was originally published in Scrip
Executive Summary
Shire has recommended its shareholders accept a $53bn (£31bn) cash and shares takeover by AbbVie. Earlier in the week the GI and rare disease drug specialist had announced it was ready to accept a bid at that level, if the terms could be pinned down satisfactorily.